Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Sickle Cell Anemia Thalassemia Patients with homozygous S/S disease or doubly heterozygous for S and β thalassemia who are 2 years or older are eligible. Patients with HbE thalassemia or homozygous (severe) β-thalassemia are also eligible. Patients with thalassemia those who are transfusion dependent (major) or severely anemic but relatively transfusion independent (intermedia). Diagnostic standard hematological parameters, red cell indices, hemoglobin electrophoresis and quantitative determination of HbF and HbA2 Patients are eligible for participation in the protocol only if they are currently clinically stable and have been free of all acute disease manifestations for a minimum of 14 days Patients may participate while continuing their current therapeutic regimen including regular transfusion therapy or hydroxyurea administration In general, two categories of patients will be considered as research participants in this protocol. 1. Patients who are 18 years or older and therefore able to provide informed consent will be eligible. Such individuals will be recruited from among patients followed at SJCRH. In addition, individuals followed in an outside clinic who are recruited will be asked to come to the Hematology Clinic at SJCRH to enroll and have the procedure performed. Alternatively, if a patient who is 18 or older is to undergo a diagnostic or surgical procedure under general anesthesia, and they agree to participate in the study, the bone marrow aspirate will be obtained at that time. 2. Patients between the ages of 2 and 17 years who are scheduled for a diagnostic or surgical procedure at SJCRH or LeBonheur Children's Medical Center for which sedation or general anesthesia is indicated will be eligible for protocol enrollment. A bone marrow aspiration will be performed during the sedation or general anesthesia for the diagnostic or surgical procedure  Active, acute manifestations of sickle cell disease including painful crisis, acute chest syndrome, cerebrovascular events or active infection Pregnant women will not be eligible for study enrollment Inability or unwillingness of the research participant or legal guardian/representative to give written informed consent will preclude enrollment on this research protocol Platelet count < 150,000/mm^3 Neutrophil count < 2000/mm^3 (unless on hydroxyurea therapy) Neutrophil count < 1000/mm^3 for patients on hydroxyurea therapy Prothrombin Time > 17 seconds Partial thromboplastin Time > 43 seconds History of excessive bleeding in the context of previous procedures including surgery and dental extractions